## Lyka Labs Limited

Corporate Office: Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036

• Phone: 6611 2200/290 Website: www.lykalabs.com • Email: enquiry@lykalabs.com



Healthcare Through Innovation

		<del></del>			(₹ in lal			
	Particulars	·. ·.	Quarter Ended			ths Ended	Year Ended	
		31st Dec, 2023	30th Sep, 2023	31st Dec, 2022	31st Dec, 2023	31st Dec, 2022	31st March, 202	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I.	Revenue	,						
	Revenue from Operations	3,141.52	2676.00	1713.20	7941.22	6113.75	8059.	
	Other Income	52.49	30.45	111.39	125.77	283.68	345.	
ı.	Total Income	3194.01	2706.45	1824.58	8066.99	6397.43	8404.	
II.	Expenses							
a)	Cost of Materials Consumed	902.10	839.03	506.87	2350.55	1772.35	2307.	
b)	Purchase of Stock in trade	296.97	233.62	113.93	890.78	574.80	719.	
c)	Change in inventories of finished goods, work-in-progress and stock-in-trade,	(23.50)	48.03	(46.12)	(87.78)	(96.34)	(120.	
d)	Employee benefits expense	699.34	620.93	430.37	1886.84	1251.20	1748.	
	Finance Costs	125.89	117.07	304.18	376.29	875.69	1157.	
f)	Depreciation and amortisation expense	271.68	346.32	332.53	951.54	1019.39	1351.	
g)	Other expenses	681.37	540.88	486.23	1666.32	1324.72	1844.	
	Total Expenses	2953.85	2745.88	2127.99	8034.54	6721.81	9007.	
<b>v.</b>	Profit / (Loss) before Exceptional Items and Taxes (II - III)	240.16	(39.43)	(303.40)	32.45	(324.38)	(603.	
٧.	Exceptional Items (Net)	0.00	4.52	689.68	4.52	703.48	717.	
/1.	Profit / (Loss) before Tax	240.16	(43.95)	(993.08)	27.93	(1027.85)	(1320.	
•••	Tax Expenses						-	
•••	Current Tax	91.00	10.00	55.45	124.50	55.45	20.	
	Deferred Tax	12.70	(24.72)	(27.20)	(31.81)			
	Deferred Tux	12.70	(24.72)	(27.20)	(31.61)	(55.18)	(12.	
III.	Net Profit / (Loss) after Tax	136.46	(29.23)	(1021.33)	(64.76)	(1028.12)	(1328.	
x.	Other Comprehensive Income			(3.18)				
	(Net of Tax) - Net Credit / (Charge)	(3.14)	0.00	(5.25)	(4.71)	(9.53)	(6.	
					-			
Κ.	Total Comprehensive Income / (Loss)	133.33	(29.23)	(1024.51)	(69.47)	(1037.65)	(1334.	
	Paid up Equity Share Capital							
	(Face value ₹ 10/- each)	3309.00	3309.00	2869.00	3309.00	2869.00	3069.	

1.The above unaudited standalone financial results were considered by the Audit Committee at its meeting held today which has been approved and taken on record at the meeting of the Board of Directors held on 8th February, 2024.

(0.10)

2. The Company operates in one reportable business segment i.e. "Pharmaceuticals".

3. The figures for the previous year have been regrouped / rearranged wherever considered necessary.

4. The Statutory Auditors have expressed an unqualified opinion on the unaudited Standalone financials results for the quarter and Nine Month ended 31st December, 2023.

For Lyka Labe Limited

(0.22)

(3.61)

(4.65)

Managing Director & CEO DIN 01516156

Mumbai; 8th February, 2024

XI. Basic and diluted earnings per share

Notes:



## D. KOTHARY & CO. Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Lyka Labs Limited

- 1. We have reviewed the accompanying statement of standalone unaudited financial results of Lyka Labs Limited (the "Company") for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34') prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.

Chartered Accountants
Firm Registration No. 105335W

Mehul N. Panel

Partner

Membership No. 132650

UDIN: 24132650BKBIFZ

Place: Mumbai

Date: February 08, 2024

Particulars

Corporate Office: Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036

Phone: 6611 2200/290 Website: www.lykalabs.com • Email: enquiry@lykalabs.com



Healtheare Through Innovation

Statement of Co	nsolidated Unudit	ed Financial Results for th	e Quarter and Nine Months Ended 31st Dec, 2023	
	. •			

٠.	ratticulais	Quarter Ended			Nine Mon	Year ended	
٠		31st Dec,	31st Sep,	31st Dec,	31st Dec,	31st Dec,	31st March,
		2023	2023	2022	2023	2022	2023
Ŀ	<u> </u>	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue						
	Revenue from Operations	3,256.38	2,798.65	1,781.56	8,342.73	7,083.42	9,307.27
1	Other Income	54.20	24.62	106.47	116.38	297.22	340.10
İ							
II.	Total Income	3,310.58	2,823.27	1,888.03	8,459.11	7,380.64	9,647.38
111.	Expenses						
(a)	Cost of Materials Consumed	902.09	839.04	506.87	2,350.55	1,772.35	2,307.57
(b)	Purchase of Stock in trade	289.39	282.04	137.90	1,025.32	1,285.54	1,568.69
(c)	Change in inventories of finished goods,	(23.54)	47.94	(46.21)	(87.94)	(96.44)	(120.81)
	work-in-progress and stock-in-trade,	1					,
(d)	Employee benefits expense	716.68	643.70	458.77	1,953.90	1,337.97	1,860.51
(e)		127.83	118.77	308.37	381.74	902.29	1,187.03
(f)	Depreciation and amortisation expense	284.16	359.47	347.43	990.32	1,068.16	1,414.73
(g)	Other expenses	685.32	568.11	502.84	1,732.22	1,429.56	2,007.33
	Total Expenses	2,981.93	2,859.07	2,215.97	8,346.11	7,699.43	10,225.05
IV.	Profit / (Loss) before Exceptional Items and Taxes (II- III)	328.65	(35.80)	(327.94)	113.00	(318.79)	(577.67)
ν.	Exceptional Items (Net)	-	43.48	701.05	43.48	698.30	739.44
VI.	Profit / (Loss) before Tax	328.65	(79.28)	(1,028.99)	69.52	(1,017.09)	(1,317.11)
VII.	Non Controlling Interest	23.31	(12.96)	(10.57)	1.93	4.78	5.94
VIII.	Profit / (Loss) before Tax	305.34	(66.32)	(1,018.42)	67.59	(1,021.87)	(1,323.05)
IX.	Tax Expenses				†	-	
	Current Tax / Earlier Year Tax	104.33	13.93	55.45	152.57	EE 45	20.45
	5.4	*******	13.33	33.43	132.37	55.45	20.45

XIV. Basic and diluted earnings per share Notes:

**Deferred Tax** 

X. Net Profit / (Loss) after Tax

XIII. Paid up Equity Share Capital

Other Equity

(Face value Rs.10/- each)

Other Comprehensive Income

(Net of Tax) - Net Credit / (Charge)

XII. Total Comprehensive Income / (Loss)

1.The above unaudited Consolidated financial results were considered by the Audit Committee at its meeting held today which has been approved and taken on record at the meeting of the Board of Directors held on 8th February, 2024.

22.91

178.10

1.10

179.20

3,309

0.53

(31.60)

(48.65)

2.14

(46.51)

3,309

(0.16)

(32.28)

0.54

(1,041.59)

(1,041.05

2.869

(3.64)

(29.76)

(55.22)

(56.69)

3,309

(0.19)

(56.88)

(5.81)

(1,020.44)

(1,026.26)

2,869

(22.32)

(3.63)

(1,321.18)

(1,324.81)

3,069

1,475

(4.63)

2. The Company operates in one reportable business segment i.e. "Pharmaceuticals".

3. The figures for the previous year have been regrouped / rearranged wherever considered necessary.

4. The Statutory Auditors have expressed an unqualified opinion on the unaudited Consolidated financials results for the quarter and Nine Month ended 31st December, 2023.

Kumal N. Gandhi Managing Director & CEO DIN 01516156

or Lyka Laba Limited

Mumbai; 8th February, 2024



## D. KOTHARY & CO. Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Lyka Labs Limited

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Lyka Labs Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

- 4. The Statement includes the results of following entities: Subsidiaries
  - i) Lyka BDR International Limited
  - ii) Lyka Exports Limited
- 5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/information reflects total revenues of Rs. 132.48 lakhs and Rs. 469.62 lakhs, total net profit/(loss) after tax of Rs. 64.95 lakhs and Rs. 11.48 lakhs and total comprehensive income of Rs. 66.09 lakhs and Rs. 14.72 lakhs for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 respectively, which have been reviewed by us.



## D. KOTHARY & CO. Chartered Accountants

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co. Chartered Accountants

Firm Registration No. 105335W

Mehul N. Patel

Partner

Membership No. 132650

UDIN: 24132650BKBIGA3245

Place: Mumbai

Date: February 08, 2024